PT  - JOURNAL ARTICLE
AU  - Mohammad E. Afshar
AU  - Haben Y. Abraha
AU  - Mohsen A. Bakooshli
AU  - Sadegh Davoudi
AU  - Nimalan Thavandiran
AU  - Kayee Tung
AU  - Henry Ahn
AU  - Howard Ginsberg
AU  - Peter W. Zandstra
AU  - Penney M. Gilbert
TI  - A 96-well culture platform enables longitudinal analyses of engineered human skeletal muscle microtissue strength
AID  - 10.1101/562819
DP  - 2019 Jan 01
TA  - bioRxiv
PG  - 562819
4099  - http://biorxiv.org/content/early/2019/02/28/562819.short
4100  - http://biorxiv.org/content/early/2019/02/28/562819.full
AB  - Three-dimensional (3D) in vitro models of human skeletal muscle mimic aspects of native tissue structure and function, thereby providing a promising system for disease modeling, drug discovery or pre-clinical validation, and toxicity testing. Widespread adoption of this research approach is hindered by the lack of an easy-to-use platform that is simple to fabricate and yields arrays of human skeletal muscle micro-tissues (hMMTs) in culture with reproducible physiological responses that can be assayed non-invasively. Here, we describe a design and methods to generate a reusable mold to fabricate a 96-well platform, referred to as MyoTACTIC, that enables bulk production of 3D hMMTs. All 96-wells and all well features are cast in a single step from the reusable mold. Non-invasive calcium transient and contractile force measurements are performed on hMMTs directly in MyoTACTIC, and unbiased force analysis occurs by a custom automated algorithm, allowing for longitudinal studies of function. Characterizations of MyoTACTIC and resulting hMMTs confirms the reproducibility of device fabrication and biological responses. We show that hMMT contractile force mirrors expected responses to compounds shown by others to decrease (dexamethasone, cerivistatin) or increase (IGF-1) skeletal muscle strength. Since MyoTACTIC supports hMMT long-term culture, we evaluated direct influences of pancreatic cancer chemotherapeutics agents on contraction competent human skeletal muscle fibers. A single application of a clinically relevant dose of Irinotecan decreased hMMT contractile force generation, while clear effects on fiber atrophy were observed histologically only at a higher dose. This suggests an off-target effect that may contribute to cancer associated muscle wasting, and highlights the value of the MyoTACTIC platform to non-invasively predict modulators of human skeletal muscle function.